340B Program

The 340B program allows qualifying safety net providers that serve a high proportion of low-income, uninsured, and underinsured patients to purchase outpatient drugs at a discounted price from pharmaceutical manufacturers. GNYHA continues to educate lawmakers on the importance of the 340B program, and will keep members informed on program updates.

11 Items in 340B Program

Sort Results

GNYHA Comments on 340B Program Implications of CMS’s Medicare Drug Price Negotiation Draft Guidance

Finance & Insurance Medicare 340B Program

MedPAC Discusses Potential Updates to the Physician Fee Schedule and New 340B Drug Data

Finance & Insurance Medicare 340B Program

GNYHA Responds to Senate Bipartisan 340B Program Discussion Draft, Request for Information

Finance & Insurance Medicare 340B Program

CMS Finalizes Medicare 340B Remedy in Response to SCOTUS Decision

November 3, 2023

Finance & Insurance Medicare 340B Program

340B Registration Requirements

November 2, 2023

Finance & Insurance Medicare 340B Program

CMS Releases Proposed Budget-Neutral Remedy to 340B Drug Payment Cuts in Response to Supreme Court Decision

Finance & Insurance Medicare 340B Program

MACs to Reprocess Medicare 2022 340B Drug Claims Upon Request; Action Required

October 19, 2022

Finance & Insurance Medicare 340B Program

HHS to Adjust 340B Rates for Remainder of 2022 Following Court Ruling

October 6, 2022

Finance & Insurance Medicare 340B Program

Supreme Court Rules in Favor of AHA on 340B Rate Cut

Finance & Insurance Medicare 340B Program

HRSA Notifies 340B Eligibility Exceptions

Finance & Insurance Medicare 340B Program

SCOTUS to Hear AHA Challenge to 340B Rate Cut, Declines to Hear Challenge to Site-Neutral Cut

Finance & Insurance Medicare 340B Program